Related Experiment Video
Updated: Mar 15, 2026

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats
Published on: March 28, 2025
ITP in children: pathophysiology and current treatment approaches
John A D'Orazio1, Jessica Neely, Nina Farhoudi
1Department of Pediatrics, Division of Hematology-Oncology and The Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY 40536-0096, USA. jdorazio@uky.edu
Pediatric immune thrombocytopenia (ITP) is a common childhood bleeding disorder. This review covers current understanding of ITP
Area of Science:
- Pediatric Hematology
- Immunology
- Bleeding Disorders
Background:
- Primary immune thrombocytopenia (ITP) is a frequent bleeding disorder in children.
- ITP often manifests as sudden bruising and petechiae in healthy children.
- It is primarily considered an antibody-mediated platelet destruction disorder.
Purpose of the Study:
- To review current concepts in pediatric immune thrombocytopenia (ITP).
- To discuss the pathophysiology of childhood ITP.
- To outline current treatment strategies for pediatric ITP.
Main Methods:
- Literature review of current concepts.
- Discussion of pathophysiology.
- Analysis of treatment approaches.
Main Results:
- ITP pathophysiology involves antibody-mediated platelet destruction.
- The condition can be self-limited or chronic.
- Various treatment strategies are available.
Conclusions:
- Understanding ITP pathophysiology is key to effective treatment.
- Management of pediatric ITP requires tailored approaches.
- Further research may improve outcomes for children with ITP.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Venous Thrombosis III: Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Regulation of Hematopoietic Stem Cells

